---

United StatesSecurities and Exchange CommissionWashington, D.C. 20549
  Form 20–F/AAmendment No.1
  [   ] Registration Statement pursuant to section 12(b) or (g) of the Securities Exchange Act of 1934 or [ X ] Annual Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2010 or [   ] Transition Report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934 or [   ] Shell Corporation Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of event requiring this Shell Corporation Reportfor the transition period from ________ to ________
  Commission File Number: 001-12033 NYMOX PHARMACEUTICAL CORPORATION(Exact name of registrant as specified in its charter)
  Canada(Jurisdiction of incorporation or organization)
  9900 Cavendish Blvd., Suite 306St. Laurent, Quebec, Canada, H4M 2V2(Address of principal executive offices)Contact person: Roy WolvinTel. 800-936-9669, e-mail: rwolvin@nymox.com,fax: 514-332-2227(name, telephone, e-mail and/or facsimile number and address of company contact person)
  Securities registered or to be registered pursuant to Section 12(b) of the Act. Title of each class

   Name of each exchange on which registeredCommon Stock

   The NASDAQ Stock Market LLC (NASDAQ Capital Market)
  Securities registered or to be registered pursuant to Section 12(g) of the Act None Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act None Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report. 32,573,856 shares as of December 31, 2010 Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [   ] No [ X ] If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Yes [   ] No [ X ] Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ X ] No [   ]


---

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate website; if any, every interactive Date File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232-405 of this chapter) during the preceding twelve months (or for such shorter period that the registrant was required to submit and post such files). Yes [   ] No [   ] Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of “accelerated filer and large accelerated filer” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer [   ] Accelerated filer [ X ] Non-accelerated filer [   ] Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing: U.S. GAAP [   ]

   International Financial Reporting Standards [   ]

   Other [ X ]as issued by the International Accounting Standards Board.
  If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow: Item 17 [   ] Item 18 [ X ] If this is an annual report, indicate by check mark whether the registrant is a shell Company (as defined in Rule 12b-2 of the Exchange Act). Yes [   ] No [ X ]


---

EXPLANATORY NOTE This Form 20-F/A is being filed by Nymox Pharmaceutical Corporation as Amendment No. 1 to its Annual Report on Form 20-F for the fiscal year ended December 31, 2010, as originally filed with the Securities and Exchange Commission on March 15, 2011 (the “Original 2010 20-F” and, as amended by this Amendment No. 1, the “2010 20-F”), to amend the Original 2010 20-F to correct an administrative error by attaching Exhibits 4(s) and 4(t) thereto as separate exhibits to the 2010 20-F, rather than as a part of the main body thereof. We are including in this Amendment No. 1 currently dated certifications by our principal executive officer and our principal financial officer. Other than as expressly set forth above, this Amendment No. 1 does not, and does not purport to, amend, update or restate the information in any other item of the Original 2010 20-F, or reflect any events that have occurred after the Original 2010 Form 20-F was originally filed.


---

ITEM 19. EXHIBITS The following exhibits are included with or incorporated by reference into this report: Exhibit No.

   Description4(s)

   Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments Limited dated November 1, 2010 (filed herewith)4(t)

   License and Collaboration Agreement between Nymox Pharmaceutical Corporation and Recordati Ireland Ltd. dated December 16, 2010 (filed herewith)12(a)

   Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) (filed herewith)12(b)

   Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) (filed herewith)13(a)

   Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)13(b)

   Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)


---

SIGNATURES The registrant hereby certifies that it meets all of the requirements for filing on Form 20-F/A and that it has duly caused and authorized the undersigned to sign this annual report on its behalf. NYMOX PHARMACEUTICAL CORPORATION(Registrant)/s/ Paul AverbackPaul AverbackTitle: President
  Date: June 3, 2011


---

EXHIBIT INDEX -NYMOX PHARMACEUTICAL CORPORATIONForm 20-F/A Annual Report
  Exhibit No.

   Description4(s)

   Common Stock Private Purchase Agreement between Nymox Pharmaceutical Corporation and Lorros-Greyse Investments Limited dated November 1, 2010 (filed herewith)4(t)

   License and Collaboration Agreement between Nymox Pharmaceutical Corporation and Recordati Ireland Ltd. dated December 16, 2010 (filed herewith)12(a)

   Certification of Principal Executive Officer Pursuant to Rule 13a-14(a) or 15d-14(a) (filed herewith)12(b)

   Certification of Principal Financial Officer Pursuant to Rule 13a-14(a) or 15d-14(a) (filed herewith)13(a)

   Certification of Chief Executive Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)13(b)

Certification of Chief Financial Officer Pursuant to 18 U.S.C. 1350, As Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)


---